Lanthanum Carbonate: Advancing therapy in Uncontrolled Hyperoxaluria

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Lanthanum Carbonate: Advancing therapy in Uncontrolled Hyperoxaluria

Hyperoxaluria leads to the formation of a particular kidney stone. Primary hyperoxaluria is a rare inherited disease caused by mutations in genes involved in the oxalate metabolism which leads to excessive endogenous oxalate synthesis resulting in increased plasma oxalate levels and hyperoxaluria.

The primary goal of hyperoxaluria management consists in the prevention of whewellite crystal formation/precipitation and ensuing kidney stone formation. Lanthanum carbonate (LC) emerged as an attractive drug for the management of uncontrolled hyperoxaluria, which is a calcium-free, non-resin based phosphate binder, which is prescribed for the management of hyperphosphatemia in patients with end-stage renal disease

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger